Genentech announces ALINA study meets primary endpoint

Genentech, a member of Roche, announced that the Phase III ALINA study evaluating Alecensa, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival, or DFS, at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected Stage IB to IIIA anaplastic lymphoma kinase, or ALK-positive non-small cell lung cancer, or NSCLC. Alecensa is the first and only ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial. Overall survival, or OS, data were immature at the time of this analysis. No unexpected safety findings were observed. Results from the ALINA study